{
  "pmcid": "6019117",
  "sha256": "74e7c859c3fc374724d1207cd95de074c7d20616820e35314b25c748a8cb6a9e",
  "timestamp_utc": "2025-11-10T00:00:17.319665+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.618739495798323,
    "reading_ease": 22.358613445378154,
    "word_count": 238
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "CHAMP: A Randomised Controlled Trial of Mesenchymal Stromal Cells in Critical Limb Ischemia"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomised to receive intramuscular injections of allogeneic MSCs (n=16) or autogenous concentrated bone marrow aspirate (cBMA, n=16)"
      },
      "Participants": {
        "score": 2,
        "evidence": "The study setting included [study location], with eligibility criteria encompassing patients with rest pain or tissue loss."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive intramuscular injections of allogeneic MSCs (n=16) or autogenous concentrated bone marrow aspirate (cBMA, n=16)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to assess the safety and therapeutic mechanisms of mesenchymal stromal cells (MSC) in patients with CLI requiring below-knee amputation (BKA)."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was proangiogenic cytokine expression, assessed at the time of amputation."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment achieved through sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "The phase I/II CHAMP trial enrolled 32 extremities with CLI requiring BKA"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "To date, ten patients have been treated per protocol."
      },
      "Result_Outcome": {
        "score": 1,
        "evidence": "Preliminary findings suggest potential efficacy in enhancing proangiogenic cytokine expression."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were monitored, with no severe events reported thus far."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}